Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd versus T-DM1 in high-risk HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy
CTR20210548Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Aug 2021; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20210548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210548.